As a translational research centre, all C4TS research is ultimately aimed at moving findings 'from the bench to the bedside', and clinical trials are a crucial step along the way. 


Clinical Trials Unit

The Clinical Trials Unit (CTU) supports C4TS with all aspects of clinical trial planning, set up, conduct, analysis and publication. We are also able to provide a CTU service for other institutions interested in conducting trials in bleeding, multiple organ dysfunction post-injury, and elderly trauma.


The 5-year TACTIC project is a multi-component study, a main focus of which is the development of a European-wide clinical trial entitled “Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (iTACTIC)”. iTACTIC is designed to find out if a rapid, detailed blood clotting test called Viscoelastic Haemostatic Assays (VHA) can be used to identify Trauma Induced Coagulopathy (TIC) early and to guide a Massive Transfusion Protocol (MTP) for that individual patient’s needs. The study will compare the outcomes of patients treated using the conventional blood transfusion strategy with the outcomes of patients treated using a personalised blood transfusion strategy guided by VHA.


Artesunate is a drug that has been in use for many years as is the treatment of choice for severe malaria.The drug appears to be enhancing the protection of organs by reducing the body’s excessive response (i.e. inflammation) to injury and blood loss, and by activating well-known cell-survival pathways. Having made this discovery in the laboratory, C4TS are preparing to conduct a Phase 2a clinical trial to test the safety and potential efficacy of Artesunate treatment in trauma patients suffering severe haemorrhage.


CRYOSTAT was a feasibility study for a multi-centre, randomised controlled trial (RCT) evaluating the effects of early administration of high-dose cryoprecipitate (i.e. a source of fibrinogen) in adults suffering major traumatic haemorrhage.This study has proven the feasibility of conducting multi-centre trauma trials focusing on the efficacy and safety outcomes of hyperacute administration of fibrinogen therapy. CRYOSTAT will greatly facilitate the design and implementation of further clinical trials (including CRYOSTAT-2 as an international definitive Phase 2a trial) that will answer the question: does early fibrinogen reduce mortality in adult patients with trauma haemorrhage?


Share this page